Media headlines about KemPharm (NASDAQ:KMPH) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. KemPharm earned a daily sentiment score of 0.05 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 45.4289065166609 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

KMPH has been the topic of a number of research reports. ValuEngine upgraded shares of KemPharm from a “strong sell” rating to a “sell” rating in a report on Saturday, July 1st. Zacks Investment Research upgraded shares of KemPharm from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Roth Capital began coverage on shares of KemPharm in a research note on Wednesday, June 28th. They issued a “buy” rating and a $8.00 price target for the company. Canaccord Genuity reissued a “buy” rating and set a $7.00 price target on shares of KemPharm in a research report on Monday, September 11th. Finally, Oppenheimer Holdings, Inc. set a $13.00 price target on shares of KemPharm and gave the company a “buy” rating in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $8.10.

KemPharm (KMPH) traded down 1.33% during mid-day trading on Friday, hitting $3.70. The company had a trading volume of 28,383 shares. The firm’s market capitalization is $54.23 million. KemPharm has a 1-year low of $2.45 and a 1-year high of $5.40. The company has a 50 day moving average of $3.09 and a 200 day moving average of $3.79.

KemPharm (NASDAQ:KMPH) last released its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.19. Analysts predict that KemPharm will post ($2.72) earnings per share for the current fiscal year.

In other KemPharm news, major shareholder Delaware Street Capital Master purchased 325,888 shares of KemPharm stock in a transaction dated Thursday, September 14th. The stock was acquired at an average price of $3.27 per share, for a total transaction of $1,065,653.76. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders bought 335,188 shares of company stock valued at $1,090,088. Company insiders own 22.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect KemPharm (KMPH) Share Price” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-kempharm-kmph-share-price/1601744.html.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Insider Buying and Selling by Quarter for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.